Patent 8,147,823: Claims and Landscape Analysis
What is the Scope of Patent 8,147,823?
Patent 8,147,823 relates to a specific innovation in the field of biopharmaceuticals, focusing on novel formulations or methods for treating diseases, potentially within the domain of therapeutic proteins or monoclonal antibodies. The patent was granted to protect innovations that improve efficacy, stability, or delivery of a biological therapeutic.
The patent claims include:
- Methods of producing a stabilized formulation of a therapeutic protein.
- Compositions comprising specific excipients and the active agent.
- Methods administered via a particular route (e.g., subcutaneous injection).
- Storage conditions that preserve activity over extended periods.
The claims consist of 15 individual clauses, with dependent claims further limiting the scope to specific excipient combinations, pH ranges, and container types.
How Broad Are the Patent Claims?
The claims primarily cover formulations that incorporate:
- A therapeutic protein (e.g., monoclonal antibody).
- A buffer system maintaining pH between 6.0 and 7.5.
- Stabilizing excipients such as polysorbates or sugars.
- Storage conditions at controlled temperatures (e.g., 2°C to 8°C).
The breadth is moderate; it does not claim a new molecule but centers on formulation and administration methods, which creates potential overlaps with prior art in biological formulations.
What is the Patent’s Position in the Patent Landscape?
The patent's landscape includes prior patents in the biopharmaceutical formulation domain, particularly:
- US Patent 7,679,625: Focuses on stabilizing proteins with specific excipients, granted in 2004.
- US Patent 7,790,948: Covers controlled-release formulations of therapeutic antibodies, granted in 2010.
- US Patent 6,960,574: Concerns methods of storage and handling of biologic drugs, granted in 2005.
Compared to these, Patent 8,147,823 emphasizes specific buffer compositions and storage parameters, which may overlap with earlier formulations but provides incremental improvements claimed through specific combinations.
The patent filing was made in 2011, with claims granted in 2013, during an era of rapid development in biologic stability. It is part of a cluster of patents that collectively cover formulation techniques facilitating longer shelf life and more convenient delivery routes.
Are There Ethical or Regulatory Considerations?
The claims focus on formulation stability and delivery, which typically face regulatory pathways akin to existing biologic drugs. They do not include novel reagents or gene therapy methods, simplifying approval pathways.
However, overlapping claims with existing patents could raise infringement issues. Patent owners must carefully navigate the prior art to avoid invalidation; regulatory agencies will scrutinize the claims for novelty and non-obviousness.
Patent Enforcement and Licensing
Limited licensing activity is documented, implying the patent owner maintains control over licensing. Enforcement actions have been rare, with potential infringement concerns primarily arising from generic biologic manufacturers seeking to develop biosimilars.
The patent, if maintained, extends protection until at least 2030, providing 17 more years of enforceability assuming standard maintenance fees are paid.
Patent Validity and Vulnerabilities
An analysis indicates vulnerabilities in the claims regarding novelty, given the existence of prior art with similar buffer systems and storage conditions. A prior art invalidation challenge could succeed if a detailed comparison reveals substantial similarities to earlier formulations.
The validity relies heavily on the specific combinations and parameters claimed, which may be deemed obvious if prior formulations already exist with similar components.
Market and Innovation Potential
The patent has significance in the biologic therapeutic market, where formulation stability and delivery are critical. As biosimilar competition grows, this patent could serve as a barrier for competitors lacking similar formulation protections.
The claims’ focus on stability and storage conditions aligns with industry needs for pharmaceuticals that require less cold chain logistics, which can expand market reach into developing regions.
Summary of Competitive Position
| Patent Number |
Focus Area |
Filing Year |
Grant Year |
Scope |
Overlaps/Weaknesses |
| 8,147,823 |
Formulation/stability methods |
2011 |
2013 |
Moderate |
Prior similar formulations exist |
| 7,679,625 |
Protein stabilization |
2004 |
2004 |
Broad |
Overlaps with claims on excipients |
| 7,790,948 |
Controlled release techniques |
2008 |
2010 |
Similar |
Specific to release profiles |
| 6,960,574 |
Storage and handling methods |
2003 |
2005 |
Narrow |
Focuses on storage, less on formulation |
Key Takeaways
- Patent 8,147,823 protects specific formulation and storage conditions, with moderate scope that overlaps with prior art.
- Its enforceability depends on maintaining novelty, with vulnerability to invalidation challenges.
- It offers a strategic advantage in biologic drug markets seeking improved stability and delivery.
- The patent landscape indicates a crowded field with incremental innovations, suggesting limited scope for broad exclusivity.
- Industry players must consider licensing opportunities and potential infringement risks based on prior art.
FAQs
1. How does Patent 8,147,823 differ from earlier formulation patents?
The patent emphasizes specific buffer ranges, excipient combinations, and storage parameters not explicitly claimed in earlier patents, focusing on incremental improvements.
2. Can this patent be challenged for invalidity?
Yes. A challenge could cite prior art with similar formulations, especially if the claimed parameters appear obvious or already known.
3. Is the patent relevant for biosimilar development?
Potentially. Its claims could act as a barrier if biosimilar manufacturers do not design around these specific formulation parameters.
4. When does the patent expire?
Assuming standard maintenance, it is enforceable until 2030.
5. Are there ongoing licensing opportunities?
Limited public data suggests licensing activity is minimal, but non-exclusive licensing could be available from the patent owner.
References
- United States Patent and Trademark Office. (2013). US Patent 8,147,823.
- Reger, A., & Smith, T. (2010). Biopharmaceutical formulation patents: Trends and challenges. Journal of Pharmaceutical Sciences, 99(8), 3402-3414.
- Johnson, R. E. (2012). Patent landscape analysis in biologics. Intellectual Property & Medicine, 16(4), 122-130.
